| 5PSQ-202 Biosimilars in the real world: results from an active pharmacovigilance programme in a Portuguese oncology hospital G Rigueiro, D Mendes, J Abrantes, AF Pais, A Penedones, C Alves, ... European Journal of Hospital Pharmacy 28 (Suppl 1), A154-A154, 2021 | | 2021 |
| A comparison between two recommendations to conduct and report systematic reviews on drug’s safety A Penedones, C Alves, F Batel Marques Systematic Reviews 8, 1-7, 2019 | 3 | 2019 |
| A comparison of the safety of apixaban, rivaroxaban and dabigatran: an indirect treatment comparison using real-world studies C Alves, D Mendes, F Batel-Marques DRUG SAFETY 42 (10), 1226-1227, 2019 | | 2019 |
| A Cumulative Meta-Analysis Evaluating the Risk of Cataracts Associated with Statins C Alves, D Mendes, FB Marques PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 26, 200-201, 2017 | | 2017 |
| A meta-analysis evaluating the risk of ophthalmic adverse events associated with MEK inhibitors. C Alves, I Ribeiro-Vaz, A Penedones, D Mendes, F Batel-Marques DRUG SAFETY 39 (10), 1037-1037, 2016 | | 2016 |
| A meta-analysis of serious adverse events reported with exenatide and liraglutide: Acute pancreatitis and cancer C Alves, F Batel-Marques, AF Macedo Diabetes Research and Clinical Practice, 2012 | 215 | 2012 |
| A Pilot Intensive Safety Surveillance Scheme for Medicines Under Additional Monitoring Used in the Treatment of Cancer A Penedones, D Mendes, G Rigueiro, F Batel-Marques, C Alves, R Sousa, ... DRUG SAFETY 42 (10), 1233-1233, 2019 | | 2019 |
| A systematic review and meta-analysis evaluating the association between fluoroquinolones use and development of retinal detachment. C Alves, A Penedones, D Mendes, F Batel-Marques PHARMACOTHERAPY 35 (5), E72-E72, 2015 | | 2015 |
| A systematic review and meta‐analysis of the association between systemic fluoroquinolones and retinal detachment C Alves, A Penedones, D Mendes, F Batel Marques Acta ophthalmologica 94 (5), e251-e259, 2016 | 32 | 2016 |
| A systematic review of economic evaluation studies of ophthalmic drugs. I Ribeiro, F Batel-Marques, C Alves PHARMACOTHERAPY 38 (7), E77-E77, 2018 | | 2018 |
| A SYSTEMATIC REVIEW OF ECONOMIC STUDIES EVALUATING OPHTHALMIC DRUGS: AN ANALYSIS OF THE EFFECTIVENESS OUTCOMES. FB Marques, D Alves, C Alves ISPOR Europe 2019, 2019 | | 2019 |
| A systematic review of economic studies evaluating ophthalmic drugs: an analysis of the health-state utilities I Ribeiro, F Batel Marques, D Mendes, C Alves Ophthalmic Epidemiology 27 (5), 325-338, 2020 | 2 | 2020 |
| A systematic review of observational studies evaluating costs of adverse drug reactions F Batel Marques, A Penedones, D Mendes, C Alves ClinicoEconomics and outcomes research, 413-426, 2016 | 80 | 2016 |
| A systematic review of the methodological quality of economic studies evaluating ophthalmic drugs I Ribeiro, F Batel Marques, D Alves, C Alves VALUE IN HEALTH 21, S429-S429, 2018 | | 2018 |
| A systematic review of the methodological quality of economic studies evaluating ophthalmic drugs IS Ribeiro, FJ Batel Marques, DG Alves, CMC Alves Expert review of pharmacoeconomics & outcomes research 19 (4), 421-430, 2019 | 6 | 2019 |
| A very unexpected cause of chronic urticaria M Araujo Leiria Pinto, C Alves, S Prates, P Leiria Pinto ALLERGY 74, 617-618, 2019 | | 2019 |
| ACUTE PANCREATITIS ASSOCIATED WITH EXENATIDE AND LIRAGLUTIDE: A META-ANALYSIS C Alves, F Batel-Marques, AF Macedo Revista Portuguesa de Farmacoterapia 4 (3), 28-38, 2012 | | 2012 |
| Acute Pancreatitis Associated with GLP-1 Agonists (Exenatide and Liraglutide) Exposure: A Meta-Analysis of Published Evidence C Alves, AF Macedo, F Batel-Marques PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 21, 238-238, 2012 | | 2012 |
| Acute pancreatitis associated with GLP-1 Agonists (Exenatide and Liraglutide) exposure: a meta-analysis of published randomized controlled clinical trials C Alves, F Batel-Marques PHARMACOTHERAPY 32 (5), E113-E113, 2012 | | 2012 |
| Adverse Events Associated with Canagliflozin Mechanism of Action: A Meta-Analysis of Randomized Clinical Trials C Alves, A Penedones, D Mendes, F Batel-Marques DRUG SAFETY 37 (10), 861-861, 2014 | | 2014 |
